Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor lysate-pulsed dendritic cell vaccine + poly-ICLC
- Development stage
- Unknown
- Lead developer
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intramuscular
01
Overview
A personalized cancer immunotherapy consisting of autologous dendritic cells (DCs) pulsed with tumor lysate antigens derived from the patient's own resected tumor tissue, administered in combination with poly-ICLC (a TLR3 agonist). The dendritic cells are harvested from the patient's blood, matured, and "pulsed" with the tumor lysate to present a broad spectrum of patient-specific tumor antigens. Poly-ICLC acts as a molecular adjuvant to enhance the immune response by mimicking viral RNA and activating Toll-like receptor 3 (TLR3) and MDA5, thereby promoting DC maturation and T-cell activation. This combination is being developed by the Jonsson Comprehensive Cancer Center at UCLA for the treatment of malignant gliomas, including glioblastoma multiforme.
- Brand names
- Hiltonol
- Other names
- tumor-lysate pulsed DC vaccination + polyICLCATL-DC + poly-ICLCautologous tumor lysate-pulsed DC vaccination + adjuvant polyICLC
02
Targets
IFIH1 (MDA5)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on autologous tumor lysate-pulsed dendritic cell vaccine + poly-ICLC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor lysate-pulsed dendritic cell vaccine + poly-ICLC.